“As we advance our innovative RAS(ON) inhibitors through late-stage development and prepare for potential commercialization, we are scaling the effort to meet the ever-growing opportunities afforded by our pipeline,” said Mark A. Goldsmith, chief executive officer and chairman of Revolution Medicines (RVMD). “With our maturing pipeline, organizational capabilities and recently bolstered financial wherewithal, we are on a path toward becoming a fully integrated, global oncology company with an industry-leading franchise of targeted therapies for patients with RAS-addicted cancers.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines publishes zoldonrasib research in Science
- Revolution Medicines announces FDA BTD to elironrasib
- Revolution Medicines: Buy Rating Backed by Strategic Focus and Promising Clinical Developments in Precision Oncology
- Revolution Medicines initiated with a Buy at Goldman Sachs
- Revolution Medicines: Strategic Growth and Financial Stability Drive Buy Rating